Evidence map›Paper›PMID 24180001›Full record

Trial reportAIDS (London, England)2013

Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection.

Josué Pérez-Santiago, Sara Gianella, Marta Massanella, Celsa A Spina, Maile Y Karris, Susanna R Var, Derek Patel, Parris S Jordan, Jason A Young, Susan J Little and 2 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in AIDS (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.

  1. The Impact of Human Immunodeficiency Virus Infection on Gut Microbiota α-Diversity: An Individual-level Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Microbiota signatures associated with invasiveFrontiers in cellular and infection microbiology · 2023
    Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Josué Pérez-Santiago
Sara Gianella
Marta Massanella
Celsa A Spina
Maile Y Karris
Susanna R Var
Derek Patel
Parris S Jordan
Jason A Young
Susan J Little
Douglas D Richman
Davey M Smith
University of California, San Diego · USVA San Diego Healthcare System · US

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer E Iudicello · 2001 to 2026
$50.4M
Transmission ProbabilityP01AI074621 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2008 to 2012
$23.1M
Primary Infection Resource Consortium (PIRC)R24AI106039 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2013 to 2021
$23.1M
Southern California Primary Infection ProgramU01AI043638 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICHMAN, DOUGLAS D · 1998 to 2010
$21.3M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitU01AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 2007 to 2011
$19.3M
HOPE Training GrantT32AI007384 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Sara Gianella Weibel, Scott L Letendre · 1990 to 2026
$9.7M
Viral correlates of neutralizing antibody responseU19AI090970 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI POIGNARD, PASCAL · 2010 to 2014
$9.3M
Molecular Epidemiology for HIV Prevention for Drug Users and Other Risk Groups DP1DA034978 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SMITH, DAVID MITCHELL · 2012 to 2016
$4.1M
A Multi-Site Investigation into the Effect of HIV Clade on Neurocognitive ImpairmR01MH083552 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SMITH, DAVID MITCHELL · 2008 to 2012
$3.3M
Biomathematical analysis of viral dynamics/evolutionR01AI047745 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICHMAN, DOUGLAS D · 2001 to 2011
$3.2M
NIAID NIH HHS AI043638NIAID NIH HHS AI047745NIAID NIH HHS AI077304NIAID NIH HHS AI080353NIAID NIH HHS AI36214NIAID NIH HHS AI69432NIAID NIH HHS AI74621NIAID NIH HHS P01 AI074621NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI047745NIAID NIH HHS R21 AI047745NIAID NIH HHS R21 AI077304NIAID NIH HHS R21 AI080353NIAID NIH HHS R24 AI106039NIAID NIH HHS R56 AI047745NIAID NIH HHS T32 AI007384NIAID NIH HHS U01 AI043638NIAID NIH HHS U01 AI069432NIAID NIH HHS U19 AI090970NIAID NIH HHS U19AI090970NIAID NIH HHS UM1 AI069432NIDA NIH HHS DA034978NIDA NIH HHS DP1 DA034978NIMH NIH HHS MH083552NIMH NIH HHS MH62512NIMH NIH HHS P30 MH062512NIMH NIH HHS R01 MH083552
6 · The paper itself

Abstract

objectiveEarly HIV infection is characterized by a dramatic depletion of CD4 T cells in the gastrointestinal tract and translocation of bacterial products from the gut into the blood. In this study, we evaluated if gut bacterial profiles were associated with immune status before and after starting antiretroviral therapy (ART).

designWe evaluated the gut microbiota of men recently infected with HIV (n = 13) who were participating in a randomized, double-blind controlled trial of combination ART and maraviroc versus placebo and who were followed for 48 weeks.

methodsTo evaluate the gut microbiota of participants, we pyrosequenced the bacterial populations from anal swabs collected before and longitudinally after the initiation of ART. Associations of the gut flora with clinical variables (lymphocyte profiles and viral loads), activation and proliferation markers in peripheral blood mononuclear cells and gut biopsies (measured by flow cytometry) and markers of microbial translocation (lipopolysaccharide and soluble CD14) were performed by regression analyses using R statistical software.

resultsUsing pyrosequencing, we identified that higher proportions of Lactobacillales in the distal gut of recently HIV-infected individuals were associated with lower markers of microbial translocation, higher CD4% and lower viral loads before ART was started. Similarly, during ART, higher proportions of gut Lactobacillales were associated with higher CD4%, less microbial translocation, less systemic immune activation, less gut T lymphocyte proliferation, and higher CD4% in the gut.

conclusionShaping the gut microbiome, especially proportions of Lactobacillales, could help to preserve immune function during HIV infection.

Indexed as

AdultAnti-Retroviral AgentsBacteriaBacterial TranslocationBiotaCD4 Lymphocyte CountCD4-Positive T-LymphocytesCyclohexanesDouble-Blind MethodDrug Therapy, CombinationGastrointestinal TractHIV InfectionsHumansLactobacillalesMaleMaravirocAnti-Retroviral AgentsCyclohexanesMaravirocPlacebosTriazoles

Identifiers

PMID24180001
PMCPMC3816380
OpenAlexW2061845693

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.